ERBB2 and cervical cancer: Cervical cancer, a leading cause of cancer-related mortality in women, exhibits increased sorafenib resistance due to the Cdc25A/PKM2/ErbB2 pathway, in which Cdc25A suppresses ferroptosis by dephosphorylating PKM2 and upregulating ErbB2 expression (83).